Eliem Therapeutics, Inc. (ELYM)
USD 5.11
(-0.97%)
USD 5.11
(-0.97%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | 37.4 Million | 45.13 Million | 35.67 Million | 11.76 Million | 4.69 Million |
| Selling, General and Administrative Expenses | 9.88 Million | 18.92 Million | 12.35 Million | 2.42 Million | 677 Thousand |
| Research and Development Expenses | 15.41 Million | 26.21 Million | 23.32 Million | 9.34 Million | 4.01 Million |
| Other Expenses | - | 1.37 Million | -11.63 Million | - | 914 Thousand |
| Cost and Expenses | 37.4 Million | 45.13 Million | 35.67 Million | 11.76 Million | 4.69 Million |
| Operating Income | -21.46 Million | -45.13 Million | -35.67 Million | -20.92 Million | -7.44 Million |
| Interest Expense | - | 1.59 Million | - | - | - |
| Income Tax Expense | -21.46 Thousand | 109 Thousand | -66.55 Thousand | -9.15 Million | -2.75 Million |
| Earnings before Tax | -35.11 Million | -45.24 Million | -47.48 Million | -20.66 Million | -6.54 Million |
| Net Income | -35.11 Million | -45.35 Million | -47.48 Million | -11.51 Million | -3.79 Million |
| Earnings Per Share Basic | -1.30 | -1.72 | -1.81 | -0.44 | -0.14 |
| Earnings Per Share Diluted | -1.30 | -1.72 | -1.81 | -0.44 | -0.14 |
| Weighted Average Shares Outstanding | 26.98 Million | 26.31 Million | 26.23 Million | 26.31 Million | 26.31 Million |
| Weighted Average Shares Outstanding (Diluted) | 26.98 Million | 26.31 Million | 26.23 Million | 26.31 Million | 26.31 Million |
| Gross Margin | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - |
| Profit Margin | - | - | - | - | - |
| EBITDA | -13.65 Million | -43.65 Million | -35.5 Million | -2.86 Million | -1.93 Million |
| Earnings Before Tax Margin | - | - | - | - | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | 4.71 Million | 3 Million | 5.12 Million | 40.27 Million | 5 Million | 6.71 Million |
| Selling, General and Administrative Expenses | 3.66 Million | 1.91 Million | 1.99 Million | - | 2.12 Million | 3.02 Million |
| Research and Development Expenses | 1.04 Million | 1.09 Million | 3.12 Million | - | 2.87 Million | 3.68 Million |
| Other Expenses | 1.48 Million | - | -2.25 Million | - | - | 1.11 Million |
| Cost and Expenses | 4.71 Million | 3 Million | 5.12 Million | 40.27 Million | 5 Million | 6.71 Million |
| Operating Income | -4.71 Million | -3 Million | -5.12 Million | -40.27 Million | -5 Million | -6.71 Million |
| Interest Expense | - | - | 1.14 Million | - | - | - |
| Income Tax Expense | - | -3 Million | -3055.00 | -21.46 Thousand | -4779.00 | -506.08 Thousand |
| Earnings before Tax | -54.88 Million | -1.69 Million | -3.64 Million | -35.11 Million | -3.96 Million | -5.22 Million |
| Net Income | -54.88 Million | -1.69 Million | -3.64 Million | -35.11 Million | -3.96 Million | -5.22 Million |
| Earnings Per Share Basic | -1.81 | -0.06 | -0.13 | - | -0.15 | -0.19 |
| Earnings Per Share Diluted | -1.81 | -0.06 | -0.13 | - | -0.15 | -0.19 |
| Weighted Average Shares Outstanding | 30.34 Million | 27.63 Million | 27.69 Million | 26.98 Million | 27.07 Million | 26.84 Million |
| Weighted Average Shares Outstanding (Diluted) | 30.34 Million | 27.63 Million | 27.69 Million | 26.98 Million | 27.07 Million | 26.84 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -4.71 Million | -3 Million | -5.12 Million | - | -5 Million | -7.09 Million |
| Earnings Before Tax Margin | - | - | - | - | - | - |
PHIL
5574
KESORAMIND
WELPP
MASI
CENTEXT